ALPMF (Astellas Pharma) Beginning Cash Position: $-0 Mil (As of Mar. 2026)


ALPMF Astellas Pharma Inc ALPMF
77 GF Score
Price $12.85
GF Value $13.34
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Beginning Cash Position?

Astellas Pharma ALPMF -9.82% 77 Beginning Cash Position is $-0 Mil as of Mar. 2026. GuruFocus rates ALPMF with a GF Score™ of 77/100 and a GF Value™ of $13.34 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Astellas Pharma's Beginning Cash Position for the quarter that ended in Mar. 2026 was $-0 Mil.

Astellas Pharma's quarterly Beginning Cash Position increased from Sep. 2025 ($-0 Mil) to Dec. 2025 ($1,841 Mil) but then declined from Dec. 2025 ($1,841 Mil) to Mar. 2026 ($-0 Mil).

Astellas Pharma's annual Beginning Cash Position declined from Mar. 2024 ($2,515 Mil) to Mar. 2025 ($2,252 Mil) and declined from Mar. 2025 ($2,252 Mil) to Mar. 2026 ($1,187 Mil).

Astellas Pharma Beginning Cash Position Related Terms

Astellas Pharma Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Beginning Cash Position Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,750.34 2,364.03 2,515.31 2,252.06 1,187.09

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 1,303.76 -0.00 1,841.09 -0.01
ALPMF
77GF Score
Astellas Pharma Inc ALPMF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $-0 Mil mean?
Astellas Pharma (ALPMF) has a Beginning Cash Position of $-0 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Beginning Cash Position too high?
Astellas Pharma's current Beginning Cash Position is $-0 Mil. Overall, Astellas Pharma has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Beginning Cash Position compare to LLY and JNJ?
Astellas Pharma's Beginning Cash Position of $-0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Beginning Cash Position is $-0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.34, compared to a current price of $12.85 — trading 3.7% below its estimated fair value. The current Beginning Cash Position is $-0 Mil. Astellas Pharma's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Beginning Cash Position is $-0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $12.85 is trading 3.7% below its estimated GF Value™ of $13.34. GuruFocus considers Astellas Pharma to be Modestly Undervalued.

Key valuation signals for ALPMF:

  • Beginning Cash Position: $-0 Mil
  • GF Value™: $13.34 vs. price of $12.85 (3.7% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
77GF Score

Get the complete analysis for ALPMF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.85
Price
$13.34
GF Value